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Abstract Precise identiWcation of regulatory T cells is
crucial in the understanding of their role in human cancers.
Here, we analyzed the frequency and phenotype of regula-
tory T cells (Tregs), in both healthy donors and melanoma
patients, based on the expression of the transcription factor
FOXP3, which, to date, is the most reliable marker for
Tregs, at least in mice. We observed that FOXP3 expres-
sion is not conWned to human CD25+/high CD4+ T cells, and
that these cells are not homogenously FOXP3+. The circu-
lating relative levels of FOXP3+ CD4+ T cells may Xuctuate
close to 2-fold over a short period of observation and are
signiWcantly higher in women than in men. Further, we
showed that FOXP3+ CD4+ T cells are over-represented in
peripheral blood of melanoma patients, as compared to
healthy donors, and that they are even more enriched in
tumor-inWltrated lymph nodes and at tumor sites, but not in
normal lymph nodes. Interestingly, in melanoma patients, a
signiWcantly higher proportion of functional, antigen-expe-
rienced FOXP3+ CD4+ T was observed at tumor sites,
compared to peripheral blood. Together, our data suggest
that local accumulation and diVerentiation of Tregs is, at
least in part, tumor-driven, and illustrate a reliable combi-
nation of markers for their monitoring in various clinical
settings.
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Introduction
Accumulating evidence suggests that a thymus-derived
population of natural regulatory T cells (Tregs) play a cen-
tral role in controlling immune responsiveness to self- and
allo-antigens [39].
CD4+ T cells constitutively expressing high levels of the
IL-2 receptor  chain (CD25) were found to be enriched for
immunosuppressive activity. In mice, absence of these cells
leads to early appearance of a combination of multiple
autoimmune manifestations, culminating in a wasting dis-
ease. Adoptive transfer of animals with CD4+ CD25+ T
cells inhibits the development of autoimmunity by sup-
pressing self-reactive T cells in the periphery. Nevertheless,
the value of CD25 as a biomarker for regulatory T cells is
limited, particularly in humans, since it is also expressed on
recently activated CD4+ and CD8+ T cells.
FOXP3, a member of the FOXP family of transcription
factors (FOXP1–4), has recently been discovered as a
major marker and functional regulator of Treg cell develop-
ment. This Wnding brought out the possibility for a better
characterization of Tregs in both mouse and humans
[16, 47, 51]. Mutations in the foxp3 gene were linked
to autoimmune manifestations observed in the Scurfy
mouse [9] and in humans with the IPEX syndrome, a lethal
X-linked disease characterized by immune deregulation,
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1796 Cancer Immunol Immunother (2008) 57:1795–1805polyendocrinopathy, and enteropathy [6, 8]. Transfection of
FOXP3 in CD4+ CD25¡ naive T cells can convert them to
functionally and phenotypically natural Treg-like cells
[22]. Moreover, a recent report on the function of IL-2 in
foxp3-expressing cells showed that foxp3+ CD4+ T cells
normally develop in IL2¡/¡ and IL2R¡/¡ mice, and
are fully able to suppress T cell proliferation in vitro [15].
Recent observations suggest that FOXP3 cooperates with
NFAT, and physical interaction between these two molecules
switches the activation program of a T cell into a suppressor
program [50]. These results indicate that FOXP3 is a
master control gene for the development and function of
natural Treg.
CD4+ T cells play an important, but dual role in regulat-
ing host immune responses against cancer. On one hand,
the combined and concomitant activation of both helper
CD4+ T cells and cytolytic CD8+ T cells greatly potentiate
the eradication of tumor cells. On the other hand, the pres-
ence of CD4+ T cells displaying suppressive activity at the
tumor site may play a signiWcant role in inhibiting anti-
tumor immunity [25].
In human cancer, a state of local immune tolerance,
concerning both CD8+ T cell activation and function, has
recently been reported [2, 21, 53]. Multiple mechanisms
have been postulated for being responsible for preventing
an eYcient anti-tumor response: from the tumor cell side,
diVerent escape mechanisms have been described (e.g.,
down regulation of HLA molecules, loss of expression of
tumor-associated antigens, secretion of inhibitory cyto-
kines, lack of costimulatory molecules) [2, 18, 24]. From
the immune cell side, the accumulation of lymphocytes
with suppressive function could abrogate the anti-tumor
cytotoxic response. An increased prevalence of CD25+
CD4+ T cells in peripheral blood or at tumor sites in
patients bearing diVerent types of epithelial cancer sug-
gest that these cells are Tregs inhibiting an eYcient anti-
tumor cytotoxic response [11, 23, 28, 46, 49]. However,
the majority of data available to date on FOXP3+ CD4+ T
cells in human cancers mainly focused on their monitor-
ing by immunohistochemical analysis in biopsy of tissue
sections [4, 13, 29–31, 33], with the consequent impossi-
bility of a multiparametric monitoring, an exact quantiW-
cation of Tregs in diVerent body compartments, and an
evaluation of their functionality. Flow cytometric detec-
tion of FOXP3+ CD4+ T cells at the single cell level has
been illustrated in several recent human cancer reports,
while the Xow cytometric Treg cell monitoring mainly
relied on the evaluation of CD4+ CD25+ T cells [14, 20,
26, 42, 48].
The purpose of our study was to directly characterize, by
Xow cytometry, the population of FOXP3+ CD4+ T cells
in humans, both in healthy donors (HDs) and melanoma
patients.
Materials and methods
Tissues and cells
Peripheral blood (n = 42), metastatic lymph nodes (LNs)
(tumor-inWltrated lymph nodes or TILN, n = 10), normal
LNs diagnosed as tumor free by pathological examination
(NLN, n = 10), and non-lymphoid tissue metastases (TIL,
n = 3) were obtained from a total of 42 patients (stage III–
IV, mean age: men 60.7, women 55.3 years). Informed con-
sent was obtained from all patients (Lausanne University
Hospital, Switzerland). Peripheral blood was obtained
from healthy adult donors at the blood transfusion centre
(Lausanne, Switzerland) (mean age: men 44.7, women
45.3 years). Cord blood samples were obtained from umbil-
ical cord veins immediately after delivery of the placenta
(University Hospital of Ghent, Belgium). Mononuclear
cells were puriWed and immediately frozen as described
previously [35].
Antibodies and Xow cytometry
MAbs were from Becton Dickinson (San José, CA; anti-
human CD25-PE, CD4-PECy7, CD127 puriWed, CD27-
Alexa750, CD45RA-ECD, CCR7-puriWed, CTLA-4-APC
or CTLA-4-PECy5, GAM-FITC, GAR-APC antibodies),
except for anti-human-FOXP3-FITC (clone PCH 101) and
CD127-paciWc blue antibodies (eBiosciences, San Diego,
CA), and were used according to the manufacturer’s recom-
mendations. Thawed, cryopreserved PBMCs were stained
in triplicates for healthy donors or monoplicates for mela-
noma patients. First, staining for cell surface markers was
performed at 4°C. After wash, cells were Wxed, subse-
quently permeabilized with the eBiosciences Kit, and
stained intracellularly for FOXP3.
Lymphocytes were gated according to their forward and
side scatter characteristics, collected using a FACSCanto or
LSRII, and analysis was performed using the CellQuest
software (BD Biosciences, San José, CA).
Proliferation assay
Proliferation assays were performed using highly pure, Xow
cytometry-based sorted CD4+ CD25+ CD127¡ and CD4+
CD25¡ CD127+ T cells, from PBLs of HDs (n = 4), PBLs
from melanoma patients (n = 4), and from TILN of mela-
noma patients (n = 3). The gating strategy for sorting is
shown in Fig. 4d, left panel. Upon re-analysis of the Xow
cytometry-based sorted populations, purity was >95%.
CD4+ CD25+ CD127¡ and CD4+ CD25¡ CD127+ T cells
were cultured alone or co-cultured at 1:1 ratio in triplicates,
with irradiated allogenic PBMCs, in 96-well round-bottom
plates in RPMI 1640, with 8% heat-inactivated pooled123
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last 18 h before harvesting and measuring scintillation
counts. Inhibition of proliferation was calculated as fol-
lows: [1 ¡ (proliferation of Tresp + Tregs in co-culture)/
(proliferation of T responders alone + proliferation of Tregs
alone)] £ 100.
Statistical analysis
The signiWcance of the results was determined using the
Student t test. P values <0.05 were considered statistically
signiWcant.
Results
FOXP3 and CD25 expression in human CD4+ T cells in 
HDs and melanoma patients
Lymphocytes from cord and peripheral blood of HDs
as well as from peripheral blood, normal lymph nodes
(NLNs), and TILNs from melanoma patients, were puriWed
and stained with anti-CD4 and anti-CD25 antibodies and,
once Wxed and permeabilized, with anti-FOXP3 antibody
(Fig. 1a). To establish the relationship between the two
markers, electronically set gates according to increasing
expression of CD25 were drawn on CD4+ T cells (Fig. 1b)
and percentages of FOXP3+ cells as well as mean Xuores-
cence intensity (MFI) values of FOXP3 expression were
assessed in each subset (Fig. 1c, d, respectively). While a
signiWcant number of CD25+ cells expressed the FOXP3
marker, a proportion of FOXP3+ cells was clearly detect-
able in the CD25 intermediate and low subsets, as previ-
ously described for HDs [37]. For instance, in the NLN
lymphocyte population, close to 50% of FOXP3+ CD4+ T
cells expressed a CD25low phenotype. For the same propor-
tion of FOXP3+ CD4+ T cells, CD25 expression was
greater in the PBL and TILN populations from a cancer
patient, and even higher for cord blood and PBL of healthy
donor origin. Thus, in samples from melanoma patients
(both from peripheral blood and TILNs), high percentages
of CD25 intermediate cells were positive for the FOXP3
marker. In contrast, an important proportion of the
CD25high cells (up to 30%) did not display any detectable
FOXP3 expression, possibly corresponding to a population
of recently activated T cells in the tumor-inWltrated tissues.
Fig. 1 Correlation between FOXP3 and CD25 expression on diVerent
CD4+ human T cell subsets. Human lymphocytes puriWed from cord
blood (CB), peripheral blood (PBL), normal lymph nodes (NLN), or tu-
mor-inWltrated lymph nodes (TILN) were stained using a combination
of anti-CD4, anti-CD25, and anti-FOXP3 antibodies. a Representative
dot plot for CD25 and FOXP3 staining is shown. Dot plot is gated on
CD4+ cells. b Rectangular gates from 1 to 11 were drawn on CD4+ T
cells according to increasing expression of the CD25 antigen, as la-
beled with a PE-conjugated antibody. c Percentages of FOXP3 positive
cells were calculated for CD4+ T cells in each gate using CellQuest
software. Representative examples for HDs and patients are shown.
d Mean Xuorescence intensity (MFI) of FOXP3 is shown for CD4+ T
cells in each gate. Representative examples for HDs and patients are
shown
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CD25, in a similar manner in healthy donors (HDs) com-
pared to patients. No detectable expression of FOXP3 on
CD8+ T cells was observed by Xow cytometry, even if
some of the cells were CD25 positive. No signiWcant stain-
ing was seen using an isotype matched control IgG–FITC
(data not shown).
Treg kinetics in healthy donors’ peripheral blood
Limited data are available to date on the frequency of
FOXP3+ CD4+ T cells in cord blood and peripheral blood
from HDs [17]. We found mean values of 3.5% (n = 4,
range 1.6–6.2) and 2.9% (n = 53, range 1.1–5.7) of CD4+ T
cells expressing the FOXP3 protein in cord and peripheral
blood, respectively.
To compare results from HDs and patients, we Wrst con-
ducted a study to assess the variation of FOXP3+ CD4+ T
cell number in peripheral blood of HDs over time. In six
HDs, three men and three women, the percentages of total
CD4+ as well as FOXP3+ CD4+ T cells were monitored
over a period of 2 months, with two additional late time
points at 12 and 13 months. Overall percentages of total
CD4+ T cells were stable over time in all individuals tested.
Values ranged from 27.6 to 57.8% in the diVerent donors,
with a mean coeYcient of variation (CV) over time of 6.9%
(range 2.5–14.4) (data not shown).
Mean values of 2.4% (range 0.6–3.8) for men and 3.5%
(range 2.4–7.6) for women of FOXP3+ cells in total CD4+ T
cells were observed (Fig. 2a). The levels of FOXP3+ CD4+
T cells in women were higher than those measured in men.
The values of FOXP3+ CD4+ T cells during the monitoring
period showed a higher variability if compared to the per-
centages of total CD4+ T cells, with a mean CV of 35.3%
(range 18.6–59.9). The stability and reproducibility of the
assay were tested by repeatedly performing triplicate stain-
ing on the individual samples for each donor and each time
point, with a mean CV of 6.9% (range 0.7–19). In addition,
Fig. 2 Longitudinal study of FOXP3 expression on human CD4+ T
cells in healthy donor (HD) blood. a Human lymphocytes puriWed from
peripheral blood of HDs, three men (closed symbols) and three women
(open symbols), were stained using a combination of anti-CD4 and
anti-FOXP3 antibodies, in triplicates. Blood withdrawal was per-
formed over a period of 13 months, on days 0, 2, 4, 11, 25, 53, 365, and
395. All the samples, from all time points, were frozen on the day of
blood withdrawal, using the same standard operating procedure, and
the staining was performed, in triplicates, on the same day for all the
samples collected between days 0 and 4, between days 11 and 53, and
between days 365 and 395 in order to reduce possible variations due to
processing/staining. Mean percentages of FOXP3+ T cells in total
CD4+ T cells, with SE bars for each time point measured, are shown.
b Rectangular gates (G1, G2, and G3) were drawn on CD4+ T cells
according to increasing expression of the CD25 antigen, and expres-
sion of FOXP3 and CD127 in each gate is shown in representative dot
plots (left dot plots). Expression of FOXP3 and CTLA-4, as well as
FOXP3 and CD27, is shown in total CD4+ T cells (right dot plots).
Numbers represent percentages of cells in each quadrant
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CD127, CTLA-4, CD27) on the FOXP3-positive popula-
tion conWrmed that these cells display a typical Treg pheno-
type (e.g., CD127¡, CTLA-4+, CD27+) (Fig. 2b). Staining
for LAP, TGF, and GPR83 were consistently negative
(data not shown). Thus, in healthy donors, the percentages
of FOXP3+ CD4+ T cells do show Xuctuations within a
relatively short period of observation.
Increased levels of FOXP3+ CD4+ T cells in peripheral 
blood of melanoma patients
Increased levels of CD4+ CD25+/high T cells have been
reported in peripheral blood of cancer patients [11, 23, 28,
29, 42, 46, 49]. However, so far, the Xow cytometric assess-
ment of the prevalence and the phenotype of CD4+ T cells
expressing the protein FOXP3 in cancer patients have not
been explored systematically. First, 19 patients with stage
III/IV melanoma, before any treatment, were analyzed with
respect to the prevalence of FOXP3+ CD4+ T cells in
peripheral blood. A comparison between values obtained in
HDs (n = 53) and this cohort of melanoma patients revealed
a 1.7-fold increase of FOXP3+ CD4+ T cells in patients
compared to healthy individuals (Fig. 3). Mean values of
FOXP3+ T cells among total CD4+ T lymphocytes in HDs
were 2.9% (range 1.1–5.7), compared to 5.05% (range 1.8–
10.4) observed in melanoma patients. The diVerence was
statistically signiWcant (P < 0.001), in contrast to data
obtained in a previous report on CD4+ CD25high T cells,
where no statistically signiWcant diVerence was found on
comparing the frequency of CD4+ CD25high T cells in
peripheral blood of HDs and melanoma patients [46]. Sig-
niWcantly higher percentages of FOXP3+ CD4+ T cells were
found in healthy women (mean of 3.7%) compared to
healthy men (mean of 2.4%, P < 0.001); similarly, among
melanoma patients, women showed higher percentages of
FOXP3+ CD4+ T cells than men, with a mean of 5.5 and
4.5%, respectively. Yet, in the patients group, the observed
diVerence did not reach statistical signiWcance.
Increased frequency of FOXP3+ CD4+ T cells in TILNs 
and TILs of melanoma patients, compared to peripheral 
blood and normal LNs
We compared frequencies of FOXP3+ CD4+ T cells in
ex vivo samples from four distinct body compartments:
peripheral blood, NLNs, TILNs, and TILs (Fig. 4a, b;
Table 1). Paired tissue samples were collected from a series
of stage III/IV melanoma patients. The proportion of
FOXP3+ CD4+ T cells was signiWcantly increased
(P < 0.001) in the TILN (mean 17.4, range 9.1–28.3) com-
pared to autologous PBLs (mean 6.9, range 3.7–13.0). An
even higher increase was observed in TILs (mean 18.3,
range 15.0–21.0, P < 0.001). In contrast, there was no sta-
tistical diVerence between frequencies of FOXP3+ CD4+ T
cells in peripheral blood mononuclear cells and tumor-free
LNs (P = 0.73), suggesting a selective increase of FOXP3
expressing CD4+ T cells in metastatic lesions (P < 0.001
when comparing NLNs vs. TILNs or NLNs vs. TILs)
(Fig. 4b; Table 1). Thus, FOXP3+ CD4+ T cells are
increased in the tumor microenvironment of melanoma
patients.
Phenotypic characterization in terms of CD25, CD127,
CD27, and CTLA-4 of the identiWed FOXP3+ CD4+ T cells
in the diVerent samples isolated from all the body compart-
ments did not show any signiWcant diVerence. However,
CTLA-4 expression was slightly increased in a proportion
of TILN/TIL samples analyzed, yet not at a signiWcant level
if compared to their peripheral blood counterpart (Fig. 4c).
Staining for LAP, mTGF, and GPR83 were negative in all
the samples tested (data not shown).
From one particular patient, we had the opportunity to
isolate at the same time point, lymphocytes from peripheral
blood as well as from both a clinically progressing and a
clinically regressing tumor-inWltrated lymph node. Interest-
ingly, when assessing the percentage of FOXP3+ CD4+ T
cells in these diVerent samples, we detected 5.9% in the
peripheral blood, 13.7% in the progressing, while only
10.0% in the regressing lymph node.
Importantly, the detected Tregs, in both peripheral blood
and tumor-inWltrated lymph nodes, displayed an eYcient
Fig. 3 FOXP3 expression on human peripheral blood CD4+ T cells
from HDs and melanoma patients, segregated by gender. Lymphocytes
were puriWed from peripheral blood of HDs (n = 53) and melanoma
patients (n = 19) and percentages of FOXP3+ in total CD4+ T cells
were measured by Xow cytometry. Closed symbols represent values in
men, open symbols in women. Black lines represent mean percentage
values. ***P value <0.001
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1800 Cancer Immunol Immunother (2008) 57:1795–1805inhibitory function on responder T cells. Proliferation of
CD4+ CD25¡ CD127+ T cells was strongly inhibited by
autologous CD4+ CD25+ CD127¡ cells isolated by Xow
cyotmetry-based cell sorting from PBLs or TILN from mel-
anoma patients (Fig. 4d).
Increase of non-naive phenotype FOXP3+ CD4+ T cells 
in tumor-inWltrating lymph nodes, but not in normal LNs
Cord blood FOXP3+ CD4+ T cells predominantly display a
naive phenotype, with the majority of the cells co-expressing
Fig. 4 FOXP3 expression on 
CD4+ T cells in melanoma pa-
tient tissues. Lymphocytes were 
puriWed from PB, NLNs, TILNs, 
and TILs from melanoma 
patients (n = 23). Percentages of 
FOXP3+ in total CD4+ T cells 
were measured by Xow cytome-
try. a Representative histograms 
for FOXP3 staining in gated 
CD4+ T cells are shown for each 
tissue. b Black lines represent 
mean percentage values in the 
diVerent body compartments. 
Dashed line represents the mean 
value of FOXP3+ in total CD4+ 
T cells in HDs (grey area stays 
for CV). ***P value <0.001. 
c Rectangular gates (G1, G2, and 
G3) were drawn on CD4+ T cells 
according to increasing expres-
sion of the CD25 antigen, and 
expression of FOXP3 and 
CD127 in each gate is shown in 
representative dot plots for the 
diVerent tissues (left dot plots). 
Expression of FOXP3 and 
CTLA-4, as well as FOXP3 and 
CD27, is shown in total CD4+ T 
cells for the diVerent tissues 
(right dot plots). Numbers repre-
sent percentages of cells in each 
quadrant. d PuriWed CD4+ 
CD25+ CD127¡ T cells and 
CD4+ CD25¡ CD127+ T cells, 
obtained by Xow cytometry-
based cell sorting from PBLs 
from four HDs and four mela-
noma patients, and from freshly 
prepared single cell suspensions 
from three metastatic lymph 
nodes, were cultured either alone 
or at 1:1 ratio under allogeneic 
stimulation. 3[H] thymidine was 
added on day 5 for the last 18 h. 
On the left, the gating strategy 
for sorting, and on the right, the 
mean percentages and standard 
deviations of inhibition of 
proliferation, are shown
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(mean 57.8% of total FOXP3+ CD4+ T cells, data not
shown). In the peripheral blood from HDs, on the contrary,
CD4+ T cells that are positive for the FOXP3 marker are
predominantly comprised of memory cells, with a propor-
tion still being naïve (mean of 9.5% of naive cells in
FOXP3+ CD4+ T cells, n = 37) (Fig. 5a, upper panel).
Phenotypic characterization of FOXP3+ CD4+ T cells in
terms of CD45RA and CCR7 from PBLs, NLNs, and
TILNs of melanoma patients revealed a signiWcant decrease
in the CD45RA+ CCR7+ FOXP3+ CD4+ T cells in TILNs
compared to PBLs (Fig. 5a, middle and lower panels). In
contrast, comparison of percentages of naive and memory
cells among the FOXP3+ T cells in PBLs and tumor-free
LNs showed even higher levels of naive Treg cells in the
lymph nodes. When the level of naive FOXP3+ CD4+ T
cells in PBLs was arbitrarily deWned at 100%, a mean of
171 and 51% was observed in NLNs and TILNs, respec-
tively (Fig. 5b). In contrast, surprisingly, when comparing
the total CD4+ T cell population, similar levels of naive
cells were found in both tumor-free- and tumor-inWltrated-
lymph nodes, with 102 and 96%, respectively, if compared
to peripheral blood (data not shown).
Discussion
The main Wnding in this paper is the accumulation of highly
diVerentiated and functionally suppressive FOXP3+ CD4+
T cells in metastatic tumor lesions obtained from stage III
to IV melanoma patients.
Table 1 Summary of the frequencies of FOXP3+ CD4+ T cells in the
23 analyzed patients, recovered from diVerent tissues
Patients PBL LN TILN TIL
1 3.8 13.5
2 3.7 28.3
3 12.2 16.5
4 8.4 13.8
5 7.4 14.2
6 7.3 11.5
7 5.6 11.5
8 5.9 13.7
9 13 25.4
10 13 25.3
11 6.5 7.2
12 5.1 7.5
13 5.2 8
14 8.2 11.9
15 5.6 9
16 4.8 8.3
17 4.8 7.9
18 7.3 5.4
19 6.9 5.1
20 2.7 2.3
21 9.4 18.8
22 6 15
23 5 21
Fig. 5 Selective decrease of naive FOXP3+ CD4+ T cells in TILN of
melanoma patients. Lymphocytes were puriWed from peripheral blood,
normal lymph nodes, tumor-inWltrated lymph nodes from HDs (n = 37)
and melanoma patients (n = 10). Multicolor Xow cytometric analysis
was performed using a combination of anti-CD4, anti-CD45RA, anti-
CCR7, and anti-FOXP3 antibodies. a Representative dot plots of
CCR7 and CD45RA staining on FOXP3+ CD4+ T cells in PBLs from
a HD (upper panel), PBLs and NLN (middle panels), or PBLs and
TILN (lower panels) of melanoma patients LAU 1068 and LAU 435,
respectively. Numbers represent percentages of cells in each quadrant.
b Percentages of naive cells (CD45RA+ CCR7+) in FOXP3+ CD4+ T
cells in NLN or TILN of melanoma patients. The level of naive cells in
FOXP3+ CD4+ T cells in autologous PBLs, are represented by 100%
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1802 Cancer Immunol Immunother (2008) 57:1795–1805First, we determined the correlation between CD25 and
FOXP3 expression on human T cells in diVerent body com-
partments. While in cord as well as peripheral blood from
both HDs and melanoma patients, expression of FOXP3
was, as expected, present in the majority of CD25-positive
CD4+ T cells, a non-negligible proportion of CD25
expressing cells were FOXP3 negative in tumor lesions,
indicating that, besides Tregs, eVector T lymphocytes up
regulating the CD25 molecule are comprised in this popula-
tion. Moreover, in CD25int CD4+ T cells, we identiWed sub-
stantial numbers of FOXP3 expressing cells, while in
CD25low CD4+ T cells, only low but signiWcant percentages
of cells were positive for FOXP3, similar to recent pub-
lished data [27]. These observations correlate with some
recent data generated in our laboratory on human CD4+ T
cell clones. When CD4+ T cells were sorted by Xow cytom-
etry according to their CD25 expression and cloned by lim-
iting dilution, 60% of the CD25+ CD4+ sorted clones
expressed FOXP3, while the remaining clones did not
express the protein at a detectable level. The clones gener-
ated from CD25¡ CD4+ sorted cells were 100% negative
for FOXP3 (data not shown). Thus, together these data con-
Wrm and extend the consensus view that comparability and
relevance of data on Treg, deWned as CD25+ CD4+ T cells,
are diYcult and questionable.
For the validation of FOXP3 antigen as a marker identi-
fying Tregs by Xow cytometry and for their monitoring in
clinical studies, it is important to know the consistency of
the assay. In this regard, calculated inter-assay and intra-
assay CV were largely acceptable, being 6.9 and 9.7%,
respectively. However, inter individual variations in
FOXP3+ CD4+ T cells over time showed a mean CV of
35.3%, corresponding to an important Xuctuation of Tregs in
HDs. The calculated 95% conWdential interval (CI) is 1.05–
4.8% (mean § 1.96 SD). These important physiological
variations in levels of FOXP3+ CD4+ T cells in HDs should
be taken into account when interpreting past and future
reports on the direct impact of diVerent clinical manipula-
tions on Treg frequency [7, 12]. In light of the calculated
95% CI, we propose a threshold value of at least 1.8-fold
increase/decrease, when comparing treatment-induced vari-
ations in Treg frequencies to be considered signiWcantly
diVerent. Moreover, it should be kept in mind that signiW-
cant diVerences in Treg levels in the circulation are gender-
associated. It might be possible that both observations,
gender and time-dependent Xuctuations in Tregs levels, reX-
ect regulation by steroid hormones. In this regard, it is very
interesting that Xuctuations in the levels of Tregs have been
very recently reported during the menstrual cycle [5].
IdentiWed FOXP3+ CD4+ T cells also expressed high
levels of the cytotoxic-T-lymphocyte associated antigen 4
(CTLA-4) and CD27, and were negative for CD127, corre-
lating with previous observations [38, 41]. However,
FOXP3+ cells did not detectably express some other old
and new postulated speciWc Treg markers such as LAP,
membrane bound TGFß or GPR83 (data not shown) [3, 32,
34, 43]. Other speciWc cell surface markers for characteriz-
ing naturally occurring Treg in humans are currently under
investigation in our laboratory, including analyses at the
T cell clonal level.
In melanoma, recent data from a cohort of patients
revealed that tumor progression was correlated with
increased levels of circulating CD25+ CD4+ T cells, and
that a signiWcant clinical response to IL-2 therapy was only
observed in those patients who displayed a decrease in
CD25+ CD4+ T cells after treatment [10].
In a previous report on malignant melanoma, increased
frequencies of CD25+ CD4+ T cells have been observed in
TILN as compared to autologous PBLs, and their ability to
inhibit the function of inWltrating T cells has been docu-
mented [46]. Similarly, in a patient suVering from mela-
noma with malignant ascites, despite a massive inXux of
activated CD8+ T cells in the ascites Xuid, tumor progres-
sion was observed and CD25+ CD4+ T cells were increased
in the ascites Xuid and inhibited the function of anti-tumor
CD8+ T cells [21]. Since Treg frequency and function in
these studies was mostly based on total CD25+ CD4+ T
cells, while FOXP3 analysis relied on detection of the prod-
uct by PCR, we re-examined this issue by speciWcally mon-
itoring FOXP3+ CD4+ T cells by Xow cytometry, not only
in peripheral blood, but also in tissues. Interestingly, a sig-
niWcant increase of FOXP3+ CD4+ T cells was found in
PBLs of patients compared to HDs. A recent report on eight
metastatic melanoma or renal carcinoma patients [1] and
three healthy donors also hinted at such a diVerence. An
even higher prevalence of FOXP3+ CD4+ T cells was
observed in our set of tumor-inWltrated tissues, while no
diVerence was found in normal LNs, suggesting that the
presence of tumor cells induced either the localized prolif-
eration or the selective migration of FOXP3+ CD4+ T cells
to tumor-inWltrated sites. One possible scenario could be
that high levels of cytokines (e.g., IL-2, CCL22, TGF)
secreted by tumor cells possibly facilitate the attraction and
local proliferation of FOXP3+ CD4+ T cells, as well as the
in situ conversion of CD4+ T cells into Tregs [19, 45, 52,
54]. In this way, tumor cells could favor their growth
through a selective expansion of Tregs. Further studies are
necessary to dissect these hypotheses in detail.
In agreement with previously published data [17, 44], we
found a fraction of naive-phenotype Tregs in PBLs, in HDs,
as well as in melanoma patients. Strikingly, we observed a
selective decrease in the proportion of naive cells exclu-
sively among FOXP3+ CD4+ T cells in TILN, and not
among total CD4+ T cells. This observation points to tumor
antigen-driven diVerentiation of FOXP3+ CD4+ T cells.
This would imply that certain tumor-associated antigens123
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T cell proliferation, homing and diVerentiation, and thus
support a selective enrichment of FOXP3+ CD4+ T cells.
Finally, a parameter correlating with favorable clinical
outcome and survival in cancer patients is the CD8+/Treg
cell ratio present in the tumor microenvironment [36, 40].
Interestingly, in the group of melanoma patients analyzed
here, the highest CD8+/FOXP3+ CD4+ T cell ratios were
observed in two patients who showed the best clinical
course (ratio of 13.3 and 10.9), while the remaining patients
with progressing disease had clearly lower ratios (mean 1.8,
range 0.5–3.5). A more accurate evaluation will only be
possible once the ratio between CD8+/FOXP3+ CD4+ T
cells on antigen-speciWc level can be calculated. Still, our
data suggest a possible role of Treg in anti-tumor immunity
and the necessity of further characterizing them in terms of
speciWc marker expression, mechanism of inhibition, and
antigen speciWcity. Thus, novel cancer vaccine formula-
tions aiming to favor the expansion of helper CD4+ T cells,
and to limit Treg cell expansion, should be evaluated in
conjunction with CD8+ T cells and at the level of antigen-
speciWc immune responses. This may increase the chance to
identify correlations with clinical responses, and ultimately
achieve increased clinical eYcacy through immunotherapy.
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